RxDoctor Payments Data

George Crossley, MD

Cardiovascular Disease · Nashville, TNNPI 1568465623

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $131,761 of the $197,144 with a category attached, or 66.8%. Medtronic accounts for 95.0% of it on its own, with 8 other manufacturers making up the rest. Among cardiovascular disease clinicians in TN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$197,144in general payments, 2019–2025

Across 405 payments — averaging $486.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$187K
  • Philips North America LLC$7K
  • Biosense Webster, Inc.$1K
  • Abbott$983
  • Boston Scientific$729
  • Cvrx, Inc.$124
  • plus $185 from 3 others
$142,141in research payments, 2019–2025

Across 61 payments — averaging $2330.17 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Boston Scientific$106K
  • Medtronic$37K

What the payments were for

  • Consulting fees$17,0009%
  • Speaking & faculty fees$131,76167%
  • Travel & lodging$32,90717%
  • Food & beverage$15,3788%
  • Education$980%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$197,144 in reported general payments places this provider in the 95th percentile of 429 cardiovascular disease providers in Tennessee.

See all cardiovascular disease providers in Tennessee

Medicare billing

Part B allowed, 2024
$222,747
Medicare patients
1,425
Services billed
3,482

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban358$475,015
XareltoRivaroxaban87$112,030
MultaqDronedarone Hcl25$28,346
Dabigatran EtexilateDabigatran Etexilate Mesylate20$5,478
Flecainide Acetate111$5,473
Metoprolol Succinate323$4,673
Amiodarone Hcl80$2,692
Dofetilide11$839
Warfarin Sodium52$633
Metoprolol Tartrate74$610
Ramipril64$610
Carvedilol62$578
Triamterene-HydrochlorothiazidTriamterene/Hydrochlorothiazid41$537
Losartan Potassium31$524
SotalolSotalol Hcl34$466

Paid to pharmacies, not to this prescriber.

Other cardiovascular disease in Nashville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →